-->

Company Registry

ICAgen Inc (AKA:Ion Channel Advances~Neusentis~ Caldera Pharmaceuticals Inc~XRpro Sciences Inc)
Profile last edited on: 10/18/2021

Orally-administered small molecule drugs that modulate ion channel targets
Year Founded
1992
First SBIR Year
1996
Latest SBIR Award
1998
Program Status
Inactive (Acquired)

WikiProfile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

4222 Emperor Boulevard Suite 350
Durham, NC 27703
   (919) 941-5206
   info@icagen.com
   www.icagen.com
Multiple Locations:   
Congressional District:   01
County:   Durham

Public Profile

In the overall scheme of things that is the SBIR space, ICAgen has been a small bit player with a single Phase I in the mid-nineties from NIH that went to Phase II but with both awards totalling less that $700K while the amount of money flowing through the firm over time run to hundreds of millions of dollars. A complex but interesting story indicative of the development of the Pharma Medtech and Bio space, ICAgen Inc - originally dba as Ion Channel Advances, then as Neutentis, Caldera Pharmaecuticals and then as Xpro -organized around biological and computer-simulated assays to discover ion channel drugs. The firm raised significant amounts of VC when that was not easy and also went public. At various points along the way, the firm had many forms of collaborative working relationships to include in- and out licensing with many of the players in the field: corporate, other small firms, academic institutions, non-profits and federal entities. At one point acquired by Pfizer for that firm only 4-5 years later selling to assets to XRpro for $500K. The most recent posting (December 2018) indicates Roche as having signed a deal with ICAgen for the Larger firm to license the rights to develop and sell Icagen Inc.’s small molecules for difficult-to-treat CNS diseases.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
50-74
Revenue Range
5M-7.5M
VC funded?
Yes
Public/Private
Publicly Traded
Stock Info
NASDAQ : ICGN
IP Holdings
100-149

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount Project Title
1998 2 NIH $688,015
Functional Assays For Ion Channel Drug Targets

Key People / Management

  P Kay Wagoner -- President

  Douglas Krafte -- CSO

  Ben Warner -- Founder

SBIR firms in the news